1Pengo V,Pegoraro C,Iliceto S.New trends in anticoagulant therapy[J].Is Med Assoc J,2004,6(8):479-481.
2Rauova L,Poncz M,McKenzie SE,et al.Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia[J].Blood,2005,105(1):131-138.
4Ozdemir M,Erdem G,Turkoglu G,et al.Head-to-head comparison of two different low-molecular-weight heparins in acute coronary syndrome[J].Japan Heart J,2002,43(5):433-442.
5Alexander GG.Turpie.Selective factor Ⅹa inhibition with fondaparinux:from concept to clinical benefit[J].Eur Heart J Suppl,2008,10(Suppl C):C1-C7.
6Savi P,Chong BH,Greinacher A,et al.Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies:a blinded comparative multicenter study with unfractionated heparin[J].Blood,2005,105(1):139-144.
7Hirsh J,Guyatt G,Gregory W,et al.Antithrombotic and ThrombolyticTherapy,8th ed:ACCP Guidelines[J].Chest,2008,133(6_Suppl):71S-109S..
8Bauersachs RM.Fondaparinux:an update on new study results[J].Eur J Clin Invest,2005,35(1):27-32.
9Simoons ML,Bobbink IW,Boland J,et al.A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes:the pentasaccharide in unstable angina (PENTUA) study[J].J Am Coll Cardiol,2004,43(12):2183-2190.
10Yusuf S,Mehta SR,Chrolavicius S,et al.Comparison of fondaparinux and enoxaparin in acute coronary syndromes[J].N Engl J Med,2006,354(14):1464-1476.
二级参考文献3
1Goodman SG, Cohen M, Bigonzi F, et al.Efficacy and safety of subcutaneous Enoxaparin in Non-Q-Wave Coronary Events ESSENCE (1-Year Results) randomized trial of low-molecular-weight heparin (enoxaparin) vs unfractionated heparin for unstable coronary artery disease 1-year results of the ESSENCE atudy. J Am Coll Cardiol, 2000,36:693-698.
2Antman EM, McCabe CH, Gurfinkel EP, et al. Tbrombolysis in myocardial infarction -IIB TIMI-11B enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction.results of the TIMI IIB Trial. Circulation, 1999,100:1593-1601.
3Montalesot G, Collet J P, Tanguy M L, et al. Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome PAtients treated with noxaparin Circulation, 2004, 110:392-398.
1Pham PA, Pham PT, Pham PC ,et al. Implications of bleeding in acutecoronary syndrome and percutaneous coronary intervention [ J ]. Vascu-lar Health and Risk Management,2011 ,7(5) :551-567.
2Yusuf S, Mehta SR, Chrolavicius S,et al. Comparison of fondaparinuxand enoxaparin in acute coronary syndromes[ J]. N Engl J Med ,2006,354(14) :1464-1476.
3Yusuf S, Mehta SR, Chrolavicius S, et al. Effects of fondaparinux onmortality and reinfarction in patients with acute ST-segment elevationmyocardial infarction:the OASIS-6 randomized trial[ J]. JAMA,2006,295(13) :1519-1530.
4Hamm CW,Bassand JP,Agewall S,et al. ESC Guidelines for the man-agement of acute coronary syndromes in patients presenting withoutpersistent ST-segment elevation[ J] . Eur Heart J ,2011,32(23) :2999-3054.
5Mehran R,Pocock SJ, Stone GW, et al. Associations of major bleedingand myocardial infarction with the incidence and timing of mortality inpatients presenting with non-ST-elevation acute coronary syndromes : arisk model from the ACUITY trial [ J ]. Eur Heart J,2009, 30 ( 12 ):1457-1466.
6Eikelboom JW,Mehta SR, Anand SS,et al. Adverse impact of bleedingon prognosis in patients with acute coronary syndromes [ J ]. Circula-tion,2006 ,114(8) :774-782.
7Steg PG,Huber K,Andreotti F,et al. Bleeding in acute coronary syn-dromes and percutaneous coronary interventions: position paper by theWorking Group on Thrombosis of the European Society of Cardiology[J]. Eur Heart J,2011 ,32( 15) : 1854-1864.
